TaiGen Biopharmaceuticals Holdings Limited

TPEX:4157 Stock Report

Market Cap: NT$9.0b

TaiGen Biopharmaceuticals Holdings Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for TaiGen Biopharmaceuticals Holdings.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth49.3%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Here's Why We're Not Too Worried About TaiGen Biopharmaceuticals Holdings' (GTSM:4157) Cash Burn Situation

Apr 19
Here's Why We're Not Too Worried About TaiGen Biopharmaceuticals Holdings' (GTSM:4157) Cash Burn Situation

We're Not Very Worried About TaiGen Biopharmaceuticals Holdings' (GTSM:4157) Cash Burn Rate

Jan 04
We're Not Very Worried About TaiGen Biopharmaceuticals Holdings' (GTSM:4157) Cash Burn Rate

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as TaiGen Biopharmaceuticals Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TPEX:4157 - Analysts future estimates and past financials data (TWD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/2024149172-117-115N/A
6/30/2024149235-201-197N/A
3/31/2024127181-191-185N/A
12/31/202312313707N/A
9/30/2023119-161-174-166N/A
6/30/2023129-142-185-176N/A
3/31/202332-254-244-235N/A
12/31/202236-237-29-21N/A
9/30/202233-264-22-9N/A
6/30/202216-417615628N/A
3/31/20221,258786866877N/A
12/31/20211,295776617629N/A
9/30/20211,301785640650N/A
6/30/20211,3038272030N/A
3/31/202166-376-275-265N/A
12/31/202023-405-251-242N/A
9/30/202022-474-289-284N/A
6/30/202022-477-249-246N/A
3/31/202019-314-314-311N/A
12/31/201920-296-348-343N/A
9/30/201918-192-344-327N/A
6/30/201918-214-340-320N/A
3/31/201917-372-244-220N/A
12/31/201830-343-278-255N/A
9/30/201828-378-223-207N/A
6/30/201831-297N/A-256N/A
3/31/2018558776N/A-299N/A
12/31/2017553746N/A-267N/A
9/30/2017606821N/A-258N/A
6/30/2017622800N/A-278N/A
3/31/2017141-211N/A-251N/A
12/31/2016146-250N/A-153N/A
9/30/2016110-314N/A-354N/A
6/30/2016105-349N/A-416N/A
3/31/201676-422N/A-354N/A
12/31/201578-413N/A-593N/A
9/30/201578-407N/A-498N/A
6/30/201577-404N/A-470N/A
3/31/201575-428N/A-603N/A
12/31/2014105-404N/A-538N/A
9/30/2014104-450N/A-526N/A
6/30/2014102-499N/A-523N/A
3/31/2014102-448N/A-469N/A
12/31/201370-432N/A-458N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 4157's forecast earnings growth is above the savings rate (1.1%).

Earnings vs Market: Insufficient data to determine if 4157's earnings are forecast to grow faster than the TW market

High Growth Earnings: Insufficient data to determine if 4157's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 4157's revenue is forecast to grow faster than the TW market.

High Growth Revenue: Insufficient data to determine if 4157's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 4157's Return on Equity is forecast to be high in 3 years time


Discover growth companies